Hairloss cure by Replicel Rch-01| Permanent Baldness Cure by Rch-01 | Rch-01 for hairloss, baldness
Today’s video is a good news for all hair loss patients including both men and women. Yes this is on the most recent treatment for hair loss by Replicel – that’s RCH-01.
This RCH-01 hair loss treatment trial has completed its phase 1 clinical trials with some strong positive data. In this video, will know the latest happenings on this Replicel company’s RCH-01 hair restoration product, the so called permanent baldness cure.
We will also learn how this products works – that is the mechanism of action and how this is used on a patient with alopecia.
The latest news! As on On March 05 2019, RepliCel Life Sciences Inc. announced its successful completetion of phase 1 human clinical trials of its product RCH-01 – Hair Cell restoration product for the treatment of male pattern baldness or androgenetic alopecia.
The company RepliCel was first set up in Japan in 2013 and now in partnership with Shiseido, together have brought a lot of changes since then. Shiseido, has currently funded a human clinical study of RCH-01 at Tokyo Medical University Hospital and Toho University Ohasi Medical Center in Japan.
With the clinical study of RCH-01 now successfully completed in Japan, RepliCel expects Shiseido to declare its near-term plans for RCH-01.
What is RCH-01 treatment and how does this work?
RCH 01 has Alternative Names: DSC cell therapy – RepliCel; Hair cell replacement therapy – RepliCel; Human autologous hair follicle cells RepliCel Hair-01
This RCH-01 is based on the principle of advanced cellular regeneration involving the dermal sheath cup cells, hence its also called DSC cell therapy.
Replicel’s RCH-01 hair growth treatment is done by first extracting and then culturing a person’s own hair follicle cells and then re-injecting the modified DHT resistant hair follicle cells back into their scalp.
More details should be disclosed by the company once they launch the product.
The Current Status of the product: Shiseido’s Japan phase 1 clinical trial started in 3rd quarter 2016 is now complete as per company’s website and news. Now whether they enter into phase 2 or directly launch the product. Its still not clear. But likely possibility is the treatment could become available in 2020. Because of the strong positive data from this trial, there is a strong possibility that Shiseido might decide to launch the product in Japan first. So keep your fingers crossed for the launch.
RepliCel Life Sciences is developing an autologous cell-based procedure for the treatment of androgenetic alopecia (pattern baldness) and general hair loss in men and women. The procedure has the potential to become the first minimally invasive solution for hair loss.